Redeye: Active Biotech (Intervju): Redeye pratar med vd Helén Tuvesson om nuläget
2 december, 2025
Presentationer
Stora Aktiedagarna Stockholm, 25 november 2025
26 november, 2025
Redeye: Active Biotech (Intervju): Redeye pratar med vd Helén Tuvesson om nyemissionen
24 oktober, 2025
The LION Study: Safety, Tolerability and Distribution of Topical Laquinimod Eye Drops, an Innovative Immunomodulator Targeting Aryl Hydrocarbon Receptor
22 oktober, 2025
Redeye: Active Biotech: Presenation and interview with CMO Erik Vahtola and Stanford Medicine researchers
30 juni, 2025
Safety, Tolerability, and Distribution of Topical Laquinimod Eye Drops: Primary Outcomes of the Lion Study
30 juni, 2025
Redeye-videointervju med vd Helén Tuvesson
30 oktober, 2024
Huvudprövare Rebekka Schneider-Kramann presenterar den kliniska planen och positioneringen av tasquinimod i myelofibros, audiocast sammandrag
1 december, 2023
financialhearings.com – audiocast, den kliniska planen och positioneringen av tasquinimod i myelofibros
1 december, 2023
Redeye-videointervju med vd Helén Tuvesson
16 november, 2023
VD Helen Tuvesson presenterar vid Redeye Fight Cancer 2023
23 januari, 2023
Infocus-intervju med VD Helén Tuvesson på Redeye Life Science Day 2022
29 november, 2022
Active Biotechs presentation på Aktiespararnas Aktiedagen Lund, 26 september 2022
27 september, 2022
Redeye-intervju med vd Helén Tuvesson
22 augusti, 2022
Active Biotechs presentation på Aktiespararnas ”Aktiedag Lund”
28 september, 2021
VD Helen Tuvesson presenterar vid Redeye Life Science Day 2020
1 december, 2020
Laquinimod – Treatment of Inflammatory Eye Disorders
24 november, 2020
Laquinimod – Treatment of Inflammatory Eye Disorders (PDF)
24 november, 2020
Tasquinimod – Treatment of Multiple Myeloma
24 november, 2020
Tasquinimod – Treatment of Multiple Myeloma (PDF)
24 november, 2020
An Introduction to Multiple Myeloma
24 november, 2020
An Introduction to Multiple Myeloma (PDF)
24 november, 2020
A Phase 1 Study of Tasquinimod in Patients with Relapsed or Refractory Multiple Myeloma
24 november, 2020
A Phase 1 Study of Tasquinimod in Patients with Relapsed or Refractory Multiple Myeloma (PDF)
24 november, 2020
Kapitalmarknadsdag 2020
24 november, 2020